Navigation Links
Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
Date:9/16/2009

NEW HAVEN, Conn., Sept. 16 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of multi-antibiotic resistant infections, today announced that Tony Zook has been appointed to the Company's Board of Directors, succeeding Joseph Amprey, MD, Ph.D.

Mr. Zook is President of MedImmune, Chief Executive Officer of AstraZeneca North America, and Executive Vice President of Global Marketing AstraZeneca. MedImmune was acquired by AstraZeneca in June 2007. As Chief Executive Officer of AstraZeneca North America, Mr. Zook oversees AstraZeneca's business in the region, including MedImmune, the AstraZeneca US Business and the AstraZeneca Canadian Business.

A seasoned executive with more than twenty five years of experience in the pharmaceutical industry, Mr. Zook has been CEO of AstraZeneca US since 2006. He has held various sales and marketing positions in the organization, most recently serving as senior vice president for commercial operations. In that role, Zook was responsible for the company's marketing and sales organizations throughout the US. Mr. Zook joined AstraZeneca USA in 1997 and began his career in 1983 at Berlex Laboratories, where he held both sales and marketing positions.

Mr. Zook earned an associate's degree in chemical engineering from Pennsylvania State University and a bachelor's degree in biology from Frostburg University. He is a member of the board for First State Innovation, the Pennsylvania Division of the American Cancer Society and a member of the Board of Trustees for the Healthcare Leadership Council.

"As the most recent appointment to the Rib-X board, we are looking forward to working with Tony during this exciting time in the company's growth," said Dr. Susan Froshauer, President and Chief Executive Officer, Rib-X. "Tony brings years of sales and marketing experience to his new role and we believe his insight will be extremely helpful as our compounds continue to move toward commercialization."

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics, including radezolid, that can be used for the treatment of either community- or hospital-acquired infections. Rib-X has successfully completed Phase 2 trials with delafloxacin (RX-3341), a broad-spectrum fluoroquinolone with potent activity against quinolone-resistant Gram-positive bacteria, including MRSA. Radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X as an oral/IV agent for treatment of serious Gram-positive infections, has completed two Phase 2 trials. The Rx-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria, and the Rx-02 discovery program is focused on developing an IV/oral macrolide active against methicillin-resistant S. aureus, multidrug-resistant Streptococcus pneumoniae and S. pyogenes. Both delafloxacin and radezolid are currently in late-stage clinical trials.

    For further information please contact:

    Media:
    Irma Gomez-Dib
    FD Life Sciences
    Tel: 212-850-5761
    irma.gomez-dib@fd.com

    Investors:
    John Capodanno
    FD Life Sciences
    Tel: 212-850-5705
    John.capodanno@fd.com


'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Rib-X Pharmaceuticals to Present at the 49th ICAAC
2. Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria
3. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
4. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
5. Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
6. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
7. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
8. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
9. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
10. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
11. Trubion Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... Wausau, WI (PRWEB) , ... June 23, 2016 ... ... probiotic supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, ... supplements for over 35 years, is proud to add Target to its list ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
Breaking Biology Technology:
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
Breaking Biology News(10 mins):